MicroRNA‑564 inhibits the progression of non‑small cell lung cancer via targeting plexin A4

Ding,Hui; Li,Liangpeng; Gu,Biao; Ni,Yaojun; Chen,Sheng

doi:10.3892/etm.2021.9789

MicroRNA‑564 inhibits the progression of non‑small cell lung cancer via targeting plexin A4

Authors:
- Hui Ding
- Liangpeng Li
- Biao Gu
- Yaojun Ni
- Sheng Chen
View Affiliations

Affiliations: Department of Thoracic Surgery, Huai'an First People's Hospital, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China, Department of Thoracic Surgery, Nanjing First Hospital, Nanjing Medical University, P.R. China, Department of Thoracic Surgery, Hua'ian First People's Hospital, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China
Published online on: February 13, 2021 https://doi.org/10.3892/etm.2021.9789
Article Number: 358
Copyright: © Ding et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Νon‑small cell lung cancer (NSCLC) is the most frequently diagnosed type of cancer, and the most prevalent cause of cancer‑associated mortality. The present study aimed to investigate whether microRNA (miR)‑564 influences NSCLC progression by regulating NSCLC cell growth and migration, via targeting plexin A4. Therefore, the expression levels of miR‑564 and plexin A4 were evaluated in NSCLC specimens or cells using reverse transcription‑quantitative PCR. Furthermore, colony formation and Cell Counting Kit‑8 assays were performed to determine the proliferative ability of NSCLC cells. The cell migration capacity was assessed using a Transwell assay. In addition, to examine the binding ability of miR‑564 on the plexin A4 3'‑untranslated region (3'UTR), a dual‑luciferase reporter assay was performed. A mouse xenograft model was established to evaluate the effect of miR‑564 knockdown on tumor growth in vivo, whereas the expression of plexin A4 and Ki67 in NSCLC tissues was detected using immunohistochemistry. Notably, miR‑564 was downregulated in both NSCLC cell lines and tissues, while its overexpression, following transfection with miR‑564 mimics, attenuated the proliferation and proliferation, migration and invasion of NSCLC cells. By contrast, silencing of miR‑564 using a miR‑564 inhibitor promoted NSCLC cell proliferation, migration and invasion. The luciferase assay revealed that miR‑564 directly targeted the plexin A4 3'UTR in A549 and H460 cells. Additionally, the overexpression of plexin A4 rescued the effect of miR‑564 on NSCLC cell proliferation, migration and invasion abilities. Further in vivo studies demonstrated that miR‑564 knockdown promoted NSCLC growth, while miR‑564 overexpression resulted in the opposite effect in nude mice. Overall, the results of the present study revealed that miR‑564 promotes the proliferation and migration of NSCLC cells, both in vitro and in vivo, via targeting plexin A4. Therefore, miR‑564 may be considered as a possible therapeutic target for NSCLC.

View Figures

View References

1	Zhang X, Xiong Y, Xia Q, Wu F, Liu L, Zhou Y, Zeng L, Zhou C, Xia C, Jiang W, et al: Efficacy and safety of apatinib plus vinorelbine in patients with wild-type advanced non-small cell lung cancer after second-line treatment failure: A nonrandomized clinical trial. JAMA Netw Open. 3(e201226)2020.PubMed/NCBI View Article : Google Scholar
2	Innos K, Oselin K, Laisaar T and Aareleid T: Patterns of survival and surgical treatment in lung cancer patients in Estonia by histologic type and stage, 1996-2016. Acta Oncol. 58:1549–1556. 2019.PubMed/NCBI View Article : Google Scholar
3	Zare A, Ganji M, Omrani MD, Alipoor B and Ghaedi H: Gastric cancer MicroRNAs Meta-signature. Int J Mol Cell Med. 8:94–102. 2019.PubMed/NCBI View Article : Google Scholar
4	Mohr AM and Mott JL: Overview of microRNA biology. Semin Liver Dis. 35:3–11. 2015.PubMed/NCBI View Article : Google Scholar
5	Jafari N and Abediankenari S: MicroRNA-34 dysregulation in gastric cancer and gastric cancer stem cell. Tumour Biol. 39(1010428317701652)2017.PubMed/NCBI View Article : Google Scholar
6	Kanchan RK, Siddiqui JA, Mahapatra S, Batra SK and Nasser MW: microRNAs orchestrate pathophysiology of breast cancer brain metastasis: Advances in therapy. Mol Cancer. 19(29)2020.PubMed/NCBI View Article : Google Scholar
7	Gon Y, Shimizu T, Mizumura K, Maruoka S and Hikichi M: Molecular techniques for respiratory diseases: MicroRNA and extracellular vesicles. Respirology. 25:149–160. 2020.PubMed/NCBI View Article : Google Scholar
8	Liang C, Xu Y, Ge H, Xing B, Li G, Li G and Wu J: miR-564 inhibits hepatocellular carcinoma cell proliferation and invasion by targeting the GRB2-ERK1/2-AKT axis. Oncotarget. 8:107543–107557. 2017.PubMed/NCBI View Article : Google Scholar
9	Ru N, Zhang F, Liang J, Du Y, Wu W, Wang F and Liu X: MiR-564 is down-regulated in osteosarcoma and inhibits the proliferation of osteosarcoma cells via targeting Akt. Gene. 645:163–169. 2018.PubMed/NCBI View Article : Google Scholar
10	Meng FJ, Meng FM, Wu HX and Cao XF: miR-564 inhibited metastasis and proliferation of prostate cancer by targeting MLLT3. Eur Rev Med Pharmacol Sci. 21:4828–4834. 2017.PubMed/NCBI
11	Guo Y, Qi Y, Guo A, Du C, Zhang R and Chu X: miR-564 is downregulated in gastric carcinoma and targets E2F3. Oncol Lett. 13:4155–4160. 2017.PubMed/NCBI View Article : Google Scholar
12	Jiang C, Shen F, Du J, Hu Z, Li X, Su J, Wang X and Huang X: MicroRNA-564 is downregulated in glioblastoma and inhibited proliferation and invasion of glioblastoma cells by targeting TGF-β1. Oncotarget. 7:56200–56208. 2016.PubMed/NCBI View Article : Google Scholar
13	Tran TS, Kolodkin AL and Bharadwaj R: Semaphorin regulation of cellular morphology. Annu Rev Cell Dev Biol. 23:263–292. 2007.PubMed/NCBI View Article : Google Scholar
14	Matsuoka RL, Nguyen-Ba-Charvet KT, Parray A, Badea TC, Chedotal A and Kolodkin AL: Transmembrane semaphorin signalling controls laminar stratification in the mammalian retina. Nature. 470:259–263. 2011.PubMed/NCBI View Article : Google Scholar
15	Mauti O, Domaniskaya E, Andermatt I, Sadhu R and Stoeckli ET: Semaphorin6A acts as a gate keeper between the central and the peripheral nervous system. Neural Dev. 2(28)2007.PubMed/NCBI View Article : Google Scholar
16	Catalano A, Lazzarini R, Di Nuzzo S, Orciari S and Procopio A: The plexin-A1 receptor activates vascular endothelial growth factor-receptor 2 and nuclear factor-kappaB to mediate survival and anchorage-independent growth of malignant mesothelioma cells. Cancer Res. 69:1485–1493. 2009.PubMed/NCBI View Article : Google Scholar
17	Yamamoto M, Suzuki K, Okuno T, Ogata T, Takegahara N, Takamatsu H, Mizui M, Taniguchi M, Chédotal A, Suto F, et al: Plexin-A4 negatively regulates T lymphocyte responses. Int Immunol. 20:413–420. 2008.PubMed/NCBI View Article : Google Scholar
18	Kigel B, Rabinowicz N, Varshavsky A, Kessler O and Neufeld G: Plexin-A4 promotes tumor progression and tumor angiogenesis by enhancement of VEGF and bFGF signaling. Blood. 118:4285–4296. 2011.PubMed/NCBI View Article : Google Scholar
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
20	Yang B, Jia L, Guo Q, Ren H, Hu D, Zhou X, Ren Q, Hu Y and Xie T: MiR-564 functions as a tumor suppressor in human lung cancer by targeting ZIC3. Biochem Biophys Res Commun. 467:690–966. 2015.PubMed/NCBI View Article : Google Scholar
21	Wang H, Chao K, Ng SC, Bai AH, Yu Q, Yu J, Li M, Cui Y, Chen M, Hu JF and Zhang S: Pro-inflammatory miR-223 mediates the cross-talk between the IL23 pathway and the intestinal barrier in inflammatory bowel disease. Genome Biol. 17(58)2016.PubMed/NCBI View Article : Google Scholar
22	Wu Y, Heinrichs J, Bastian D, Fu J, Nguyen H, Schutt S, Liu Y, Jin J, Liu C, Li QJ, et al: MicroRNA-17-92 controls T-cell responses in graft-versus-host disease and leukemia relapse in mice. Blood. 126:1314–1323. 2015.PubMed/NCBI View Article : Google Scholar
23	Whipple AJ, Breton-Provencher V, Jacobs HN, Chitta UK, Sur M and Sharp PA: Imprinted maternally expressed microRNAs antagonize paternally driven gene programs in neurons. Mol Cell. 78:85–95.e8. 2020.PubMed/NCBI View Article : Google Scholar
24	Basak A, Munschauer M, Lareau CA, Montbleau KE, Ulirsch JC, Hartigan CR, Schenone M, Lian J, Wang Y, Huang Y, et al: Control of human hemoglobin switching by LIN28B-mediated regulation of BCL11A translation. Nat Genet. 52:138–145. 2020.PubMed/NCBI View Article : Google Scholar
25	Xiao L, Tang T, Huang Y and Guo J: MiR-564 promotes hypertrophic scar formation through TGF-β1 upregulation. G Ital Dermatol Venereol. 154:186–191. 2019.PubMed/NCBI View Article : Google Scholar
26	Song Z, Yang H, Wu X, Kong C and Xu C: microRNA-564 inhibits the aggressive phenotypes of papillary thyroid cancer by directly targeting astrocyte-elevated gene-1. Onco Targets Ther. 12:4869–4881. 2019.PubMed/NCBI View Article : Google Scholar
27	Casazza A, Laoui D, Wenes M, Rizzolio S, Bassani N, Mambretti M, Deschoemaeker S, Van Ginderachter JA, Tamagnone L and Mazzone M: Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. Cancer Cell. 24:695–709. 2013.PubMed/NCBI View Article : Google Scholar
28	He Z and Tessier-Lavigne M: Neuropilin is a receptor for the axonal chemorepellent Semaphorin III. Cell. 90:739–751. 1997.PubMed/NCBI View Article : Google Scholar
29	Podojil JR, Chiang MY, Ifergan I, Copeland R, Liu LN, Maloveste S, Langermann S, Liebenson D, Balabanov R, Chi H, et al: B7-H4 modulates regulatory CD4(+) T Cell induction and function via ligation of a semaphorin 3a/Plexin A4/Neuropilin-1 complex. J Immunol. 201:897–907. 2018.PubMed/NCBI View Article : Google Scholar